English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: BACKGROUND: Primary Biliary Cholangitis (PBC) is a rare autoimmune cause if chronic liver disease. There exists an effective treatment for these patients, ursodeoxycholic acid (UDCA), but unfortunately 30-40% of patients do not have n adequate response or cannot tolerate it. New therapies are currently being researched. A recent Canadian Institute of Health Information report suggested that there are over 500 patients in the Maritime Provinces with PBC, which was much higher than expected. This warranted a review to assess Nova Scotia’s current prevalence of PBC as part of a quality assurance and resource planning initiative in our center.

A41 PERIOD PREVALENCE ESTIMATE OF PRIMARY BILIARY CHOLANGITIS IN NOVA SCOTIA